Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study DOI Creative Commons
Chengzhi Liu, Xinyu Wang, Xusheng Cao

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 11, 2024

Corticosteroids are extensively used in ophthalmology, particularly for treating various inflammatory conditions. Despite their effectiveness, prolonged or high-dose corticosteroid use is associated with significant adverse drug reactions (ADRs), such as increased intraocular pressure, cataract formation, and secondary infections. However, there currently no systematic study comparing the side effects of ophthalmic corticosteroids. This aims to investigate safety profiles corticosteroids through pharmacovigilance analysis using FDA Adverse Event Reporting System (FAERS) database.

Language: Английский

Pro-inflammatory cytokines in stress-induced depression: Novel insights into mechanisms and promising therapeutic strategies DOI
Jun Chang,

Tingcan Jiang,

Xiaoqian Shan

et al.

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2024, Volume and Issue: 131, P. 110931 - 110931

Published: Jan. 2, 2024

Language: Английский

Citations

15
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database DOI Creative Commons
Chuan He, Qin Qiu,

S L Lu

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 12, 2025

Background Faricimab is the first and only bispecific antibody approved by U.S. Food Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding adverse events (AEs) real-world settings crucial. This study employed FDA Adverse Event Reporting System (FAERS) database to investigate potential safety concerns, with aim of providing new insights clinical practice. Methods conducted a disproportionality analysis event data from FAERS database, which faricimab was identified as primary suspect, covering period quarter 2022 second 2024. To ensure accuracy reliability study, we four types analyses: reporting odds ratio (ROR), proportional (PRR), multi-item gamma Poisson shrinker (MGPS), Bayesian confidence propagation neural network (BCPNN). Additionally, Weibull distribution utilized model risk over time. Results A total 2,735 reaction reports, were retrieved database. The showed that faricimab-induced AEs occurred across 25 system organ classes (SOCs), eye disorders meeting positive threshold all algorithms. Significant mapped preferred terms (PT), identifying reactions listed on drug label: endophthalmitis, elevated intraocular pressure, cataract, pigment epithelial tear, vitreous floaters, vasculitis, artery occlusion, vein occlusion. In addition label, several previously unreported identified, including blindness, cerebral infarction, hemorrhage, occlusive glaucoma, dry eye, metamorphopsia, unilateral blindness. Conclusion provided valuable evidence faricimab, suggesting clinicians should place greater emphasis monitoring effects during use.

Language: Английский

Citations

0
Agonism of β3-Adrenoceptors Inhibits Pathological Retinal Angiogenesis in the Model of Oxygen-Induced Retinopathy DOI Creative Commons
Alberto Melecchi, Alessio Canovai, Rosario Amato

et al.

Investigative Ophthalmology & Visual Science, Journal Year: 2024, Volume and Issue: 65(10), P. 34 - 34

Published: Aug. 26, 2024

Purpose: In response to hypoxia, sympathetic fibers the retina activate β-adrenoceptors (β-ARs) that play an important role in regulation of vascular and neuronal functions. We investigated β3-AR using mouse model oxygen-induced retinopathy (OIR). Methods: Mouse pups were exposed 75% oxygen at postnatal day 7 (PD7) followed by a return room air PD12. The preferential agonist BRL37344 was subcutaneously administered once daily different times after air. At PD17, OIR mice underwent flash pattern electroretinogram. After sacrifice, retinal wholemounts used for vessel staining or immunohistochemistry astrocytes, Müller cells, ganglion cells (RGCs). homogenates, levels markers associated with neovascularization (NV), blood–retinal barrier (BRB), astrocytes determined western blot, quantitative reverse-transcription polymerase chain reaction assess messenger. Administration antagonist SR59230A performed verify selectivity. Results: expression is upregulated but its increase prevented BRL37344, which counteracts NV inhibiting pro-angiogenic pathway, activating anti-angiogenic recovering BRB-associated markers, triggering nitric oxide production, favoring revascularization central through recovered density ultimately midperiphery. Vasculature rescue prevents dysfunctional activity OIR-associated cell loss. Conclusions: has emerged as crucial intermediary hypoxia-dependent NV, suggesting agonists treatment proliferative retinopathies.

Language: Английский

Citations

3
Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study DOI Creative Commons
Chengzhi Liu, Xinyu Wang, Xusheng Cao

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 11, 2024

Corticosteroids are extensively used in ophthalmology, particularly for treating various inflammatory conditions. Despite their effectiveness, prolonged or high-dose corticosteroid use is associated with significant adverse drug reactions (ADRs), such as increased intraocular pressure, cataract formation, and secondary infections. However, there currently no systematic study comparing the side effects of ophthalmic corticosteroids. This aims to investigate safety profiles corticosteroids through pharmacovigilance analysis using FDA Adverse Event Reporting System (FAERS) database.

Language: Английский

Citations

0